Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. is listed today as Atea Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2020 | $108 M | No. 4 | $50 to $250 million | equity | SEC | |
| Jun 2018 | $28 M | No. 3 | $10 to $50 million | equity | SEC | |
| Aug 2016 | $21 M | No. 2 | $10 to $50 million | equity | SEC | |
| Dec 2013 | $20 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Atea Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2020).
SEC Form D · May 2020
The industry group it chose in its notices: Other.
SEC Form D · May 2020
That is all the official record says: Atea Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Atea Pharmaceuticals, Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Andrea Corcoran | Person | not stated | not stated | Held Series A and B preferred stock (Form 3, 2020) | SEC Form 3 |
| Chung K. Chu | Person | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Private Healthcare Fund II, LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Private Healthcare Fund I, LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Franklin M. Berger | Person | not stated | not stated | Held Series A, B, C, D and D-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| JPM Partners LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital LLC | Fund or asset manager | not stated | not stated | Held Series D and D-1 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital Management LP | Fund or asset manager | not stated | not stated | Held Series D and D-1 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Rock Springs Capital Master Fund LP | Fund or asset manager | not stated | not stated | Held Series D and D-1 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 59 investors.
Largest shareholders today
Institutions holding Atea Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- FMR LLC$63 M14.98%
- BlackRock, Inc.$47 M11.28%
- BML Capital Management, LLC$35 M8.41%
- Tang Capital Management LLC$25 M6.00%
- Vanguard Capital Management LLC$15 M3.62%
- Acadian Asset Management LLC$12 M2.91%
- Bain Capital Life Sciences Investors, LLC$11 M2.58%
- Geode Capital Management, LLC$10 M2.38%
- State Street Corp$8 M2.03%
- Two Sigma Investments, LP$7 M1.62%
- Dimensional Fund Advisors LP$7 M1.62%
- Renaissance Technologies LLC$6 M1.36%
- Jpmorgan Chase & Co$5 M1.15%
- Northern Trust Corp$4 M0.89%
- Vanguard Portfolio Management LLC$3 M0.80%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrea Corcoran | Executive officer | May 2020 |
| Jean-Pierre Sommadossi, Ph.D. | Executive officer | May 2020 |
| Jean-Pierre Sommadossi | Executive officer | Jul 2018 |
| Andrew Hack, M.D., Ph.D. | Director | May 2020 |
| Bihua Chen | Director | May 2020 |
| Bruce Polsky | Director | May 2020 |
| Bruno Lucidi | Director | May 2020 |
| Franklin Berger | Director | May 2020 |
| Grigory Borisenko | Director | May 2020 |
| Isaac Cheng, M.D. | Director | May 2020 |
| Jean-Pierre Sommadossi, Ph.D. | Director | May 2020 |
| Evgeny Zatsev | Director | Jul 2018 |
| Fan Yu | Director | Jul 2018 |
| Gerald Chan | Director | Jul 2018 |
| Jean-Pierre Sommadossi | Director | Jul 2018 |
| Frank Yu | Director | Sep 2016 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.